Q4 2025 net product revenues of $54.3 million; 2025 full-year net product revenues of $227.3 million, representing a 49% increase over 2024 full-year net product revenues Expect significant Vafseo® (vadadustat) revenue growth in 2026 through expanded access to therapy at dialysis organizations, new patient starts, and improved adherence rates Pipeline advancement continues with enrollment underway for praliciguat Phase 2 clinical trial in focal segmental glomerulosclerosis (FSGS) and AKB-097 Phase 2 rare ...

Akebia Therapeutics Conference Summary Company Overview - **Company**: Akebia Therapeutics (NasdaqCM:AKBA) - **Focus**: Improving the lives of individuals affected by kidney disease - **Commercial Products**: - Auryxia: A phosphate binder nearing the end of its life cycle - VAFSEO: A HIF-PHI for treating anemia in chronic kidney disease patients on dialysis, launched about a year ago [4][5] Key Points on VAFSEO - **Initial Uptake**: Strong initial uptake observed post-launch, but faced challenges due to the unique nature of the dialysis market [7][8] - **Market Dynamics**: Dialysis providers control the prescription process, affecting product availability [8] - **Discontinuation Rates**: Higher than expected due to initial hemoglobin dips in patients; efforts are being made to improve patient retention [10][12] - **Dosing Strategy**: Transitioning to a three times weekly (TIW) dosing regimen has shown promising results in reducing discontinuation rates [12][13] - **Patient Access**: By the end of 2025, access to approximately 275,000 patients was achieved [13] - **Long-term Growth**: Data supporting VAFSEO's potential to become the standard of care for anemia in dialysis patients is anticipated [14][24] Clinical Trials and Studies - **VOCAL and VOICE Trials**: - VOCAL: A study comparing VAFSEO to Mircera, expected to show excellent hemoglobin control [20][29] - VOICE: A randomized comparison against Epogen, with results expected early in 2027 [29][31] - **Economic Perspective**: Demonstrating reduced hospitalization costs could enhance the economic proposition for dialysis organizations [31] Pipeline Developments - **Rare Kidney Disease Pipeline**: - Praliciguat: Phase II study initiated for FSGS, targeting rapid progression to end-stage kidney disease [5][40] - AKB-097: A tissue-targeted complement inhibitor, with a basket study planned for IgAN, C3G, and lupus nephritis [40][58] - **Mechanistic Rationale**: Praliciguat stimulates soluble guanylate cyclase, beneficial for podocytes and anti-inflammatory [42][44] - **Patient Focus**: Targeting primary FSGS and genetic mutation-related FSGS while excluding secondary causes [56] Financial Position - **Cash Reserves**: $166 million as of Q3, with at least two years of cash runway [69] Upcoming Catalysts - **Key Events**: - Continued monitoring of VAFSEO's market performance - Progress on Praliciguat and AKB-097 studies - Results from VOCAL and VOICE trials expected within the next 12 months [70][72] Conclusion - **Outlook**: The next 12 months are anticipated to be critical for Akebia, with significant clinical readouts and potential market shifts for VAFSEO and pipeline products [72]

Core Viewpoint - Unicycive Therapeutics, Inc. is actively participating in the biotech sector, focusing on developing therapies for kidney diseases, with significant upcoming events and investigational treatments under review [1][3]. Group 1: Company Overview - Unicycive Therapeutics is a clinical-stage biotechnology company dedicated to developing novel treatments for kidney diseases [3]. - The company's lead investigational treatment, oxylanthanum carbonate, is currently under review by the U.S. Food and Drug Administration (FDA) for treating hyperphosphatemia in patients with chronic kidney disease on dialysis [3]. - Unicycive's second investigational treatment, UNI-494, targets conditions related to acute kidney injury and has received orphan drug designation from the FDA for preventing Delayed Graft Function in kidney transplant patients [3]. Group 2: Upcoming Events - Shalabh Gupta, M.D., the CEO of Unicycive, will participate in a fireside chat at the Guggenheim Emerging Outlook: Biotech Summit on February 11, 2026, at 1:30 p.m. ET [1]. - A live and archived webcast of the event will be available on the Unicycive website under the Investors section [2].

Core Insights - Akebia Therapeutics is positioned to enhance the prescribing of Vafseo, targeting approximately 275,000 patients by 2026, with ongoing clinical trials and pipeline developments in rare kidney diseases [1][2] Vafseo Commercial Business - The company anticipates increased demand for Vafseo as existing customers accelerate adoption and new customers implement Vafseo protocols [2] - Vafseo is being positioned as the standard of care for treating anemia due to chronic kidney disease (CKD) in dialysis patients, supported by ongoing clinical data [2] - The company expects Q4 2025 net product revenue for Vafseo to be between $5 million and $6 million, with a projected revenue growth resuming in Q1 2026 [5] Clinical Trials and Pipeline Developments - The first patient has been dosed in the Phase 2 clinical trial for Praliciguat, targeting focal segmental glomerulosclerosis (FSGS) [1] - The AKB-097 Phase 2 rare kidney disease basket trial is set to begin in the second half of 2026, with initial data expected in 2027 [1][12] - Enrollment in the VOICE trial, a Phase IV study with over 2,100 patients, has been completed, with topline results expected in early 2027 [5] Performance Metrics - The total number of prescribers for Vafseo increased by 8% in Q4 2025, reaching approximately 785 [5] - At least 25% of new patients in Q4 2025 came from dialysis organizations other than U.S. Renal Care, up from less than 10% in Q3 [5] - The underlying patient dosing demand for Vafseo in Q4 2025 was estimated between $10.5 million and $11.5 million [5] Rare Kidney Disease Pipeline - AKB-9090, a HIF-PH inhibitor, is entering Phase 1 for acute kidney injury associated with cardiac surgery in the first half of 2026 [7] - The company plans to evaluate IgA Nephropathy, Lupus Nephritis, and C3 Glomerulopathy as part of the AKB-097 study [12]

Core Insights - Unicycive Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing therapies for kidney disease [1][2] - The company will participate in two investor events in December 2025, including the Piper Sandler 37th Annual Healthcare Conference and a Noble Capital Markets Virtual Presentation [1] Company Overview - Unicycive's lead investigational treatment is oxylanthanum carbonate, a phosphate binding agent under FDA review for treating hyperphosphatemia in chronic kidney disease patients on dialysis [2] - The second investigational treatment, UNI-494, targets conditions related to acute kidney injury and has received orphan drug designation from the FDA for preventing Delayed Graft Function in kidney transplant patients [2] - UNI-494 has completed a Phase 1 dose-ranging safety study in healthy volunteers [2]

Summary of Akebia Therapeutics FY Conference Call Company Overview - **Company**: Akebia Therapeutics (NasdaqCM:AKBA) - **Focus**: Kidney disease treatment - **Products**: - **Auryxia**: A mature phosphate binder, past patent expiry - **Vafseo**: A hypoxia-inducible factor prolyl hydroxylase inhibitor approved for treating anemia in chronic kidney disease (CKD) patients on dialysis, launched at the beginning of the year [2][3] Financial Performance - **Recent Revenue**: Reported $14.3 million in revenue for the quarter, which was below expectations despite positive underlying metrics [5] - **Market Access**: Initially had access to about 40,000 patients, which has now grown to approximately 260,000 patients due to expanded access through major dialysis providers [6] Market Dynamics - **Dialysis Providers**: - **U.S. Renal Care**: Strong clinical advocacy, significant part of revenue base - **DaVita**: Expanded access from 100 to over 4,000 dialysis centers, indicating a successful pilot program [6][14] - **Fresenius**: More challenging engagement, but potential for significant patient access if they broaden availability [20] Clinical Insights - **Patient Management**: Emphasis on educating healthcare providers about the unique dosing and administration of Vafseo compared to traditional treatments [10][12] - **Clinical Data**: Recent data presented at ASN showed a 1% decrease in mortality and an 8% lower hospitalization rate for Vafseo compared to traditional treatments [19][23] Regulatory and Reimbursement Landscape - **TDAPA**: Transitional Drug Add-on Payment Adjustment allows billing for Vafseo outside the dialysis bundle for two years, providing a higher price point and facilitating access [25][26] - **Market Size**: The anemia treatment market in dialysis is estimated at $1 billion, with potential for Vafseo to capture a significant share if it becomes standard of care [26][29] Future Outlook - **Clinical Trials**: Ongoing studies (VOICE and VOCAL) aim to provide further evidence of Vafseo's efficacy and differentiate it from existing treatments [31][32] - **Pipeline Development**: Plans to explore additional indications for HIF-PHI, including acute kidney injury and retinopathy of prematurity [38][39] Financial Position - **Cash Reserves**: Ended the quarter with $166 million, indicating a solid balance sheet and guidance towards profitability [42]

Core Insights - Vertex Pharmaceuticals is presenting updates on its kidney programs at the American Society of Nephrology Kidney Week 2025 [1][2] - The company has three kidney programs in pivotal development and one in a proof-of-concept study [2] Company Overview - The presentation is led by Susie Lisa, Senior Vice President of Investor Relations, and includes an overview from CEO Dr. Reshma Kewalramani [1] - The company expresses gratitude for the participation of three physician thought leaders who will discuss recent data on kidney disease treatments [2] Research and Development - The RUBY-3 data in IgAN will be recapped by Dr. James A. Tumlin, a prominent figure in nephrology [3] - The RAINIER Phase III study of IgAN has recently completed full enrollment in record time, indicating strong progress in clinical trials [2]

Core Insights - Arch Biopartners Inc. has received approval from the Fraser Health Research Ethics Board for the Royal Columbian Hospital to participate in the Phase II trial of LSALT peptide aimed at preventing and treating cardiac surgery-associated acute kidney injury [1][2] - The company is actively expanding its clinical trial sites, with Royal Columbian Hospital being the eighth site globally and the fourth in Canada to recruit patients [2][3] - Arch Biopartners has completed the acquisition of Lipdro Therapeutics Inc., which includes a CKD drug candidate platform, in exchange for 250,000 common shares and a royalty on future net sales [4] - The Board of Directors has granted 750,000 stock options to directors and officers, exercisable at $1.70 per share for ten years, as part of their remuneration [5] Company Developments - The ongoing Phase II trial for LSALT peptide is part of a broader initiative to address acute kidney injury, with additional sites being evaluated in Canada and the U.S. [3][9] - The acquisition of Lipdro Therapeutics enhances the company's capabilities in developing treatments for chronic kidney disease, targeting IL-32 [4] - Arch Biopartners is focused on developing novel drugs for both acute and chronic kidney diseases, addressing significant unmet medical needs globally [6]

Core Insights - Akebia Therapeutics Inc. is experiencing a decline in stock price following an unsuccessful meeting with the U.S. FDA regarding the VALOR trial design for vadadustat, aimed at treating anemia in late-stage chronic kidney disease patients not on dialysis [1][4]. Company Developments - The company has decided not to initiate the VALOR trial and will not pursue a broad label for Vafseo for non-dialysis dependent chronic kidney disease patients [2]. - Vafseo is currently approved in the U.S. for treating anemia due to chronic kidney disease in adults who have been on dialysis for at least three months, with prescriptions starting in January 2025 [2]. Regulatory Feedback - Akebia completed a Type C meeting with the FDA, which indicated that regulatory alignment for the VALOR trial would necessitate a significantly larger patient population than initially proposed, leading to increased time and costs [3]. - The CEO of Akebia expressed disappointment with the meeting's outcome but stated that the decision not to pursue a broad label is in the best interests of shareholders [4]. Market Reaction - Following the news, Akebia Therapeutics shares fell by 25.71%, trading at $2.29 at the time of publication [4].

Core Insights - XORTX Therapeutics Inc. has entered into a binding term sheet to acquire a Renal Anti-Fibrotic Therapeutic Program from Vectus Biosystems Limited, which includes the novel compound VB4-P5 and associated intellectual property [1][2] - The VB4-P5 program is at the pre-IND stage and aims to address both rare and common forms of kidney disease, which have significant unmet medical needs [1][2] Company Overview - XORTX is focused on developing innovative therapies for gout and progressive kidney disease, with a mission to provide new treatment options for patients suffering from rare renal disorders [2][8] - The company has three clinically advanced products: XRx-026 for gout, XRx-008 for autosomal dominant polycystic kidney disease (ADPKD), and XRx-101 for acute kidney injury related to respiratory virus infections [8] Acquisition Details - The acquisition consideration for Vectus is USD $3.0 million, payable in common shares or equivalents at a deemed issue price of USD $0.86 per Security [2][3] - The closing of the acquisition is expected to occur within 90 days, subject to typical conditions including regulatory approvals [3] Kidney Disease Context - Chronic kidney disease (CKD) affects approximately 14% of adults globally, translating to around 35–37 million individuals in the United States [4] - Kidney fibrosis is a key factor in CKD progression, leading to significant morbidity and mortality, with current treatments primarily focusing on blood pressure control and dietary changes [5] VB4-P5 Program Insights - Early preclinical data suggest that VB4-P5 has the potential to inhibit and possibly reverse kidney fibrosis, with patent protection covering over 30 global jurisdictions [6]